Researchers at Vanderbilt University Medical Center have achieved a milestone in the development of a potential new treatment for Parkinson’s disease that may improve on some of the limitations of current therapy.
Three drug-like molecules that act on a specific glutamate receptor in the brain are ready for the next stage of preclinical testing prior to entering human trials. The molecules were developed with major support from The Michael J. Fox Foundation for Parkinson’s Research.
If all goes well in final preclinical testing, the molecules could be ready for clinical testing as soon as 2013, says Jeffrey Conn, director of the Vanderbilt Center for Neuroscience Drug Discovery. Click here to read the rest of the article.

